ZFYVE19 Inhibitors
ZFYVE19 inhibitors comprise a chemical class that targets the ZFYVE19 protein, also known as the zinc finger FYVE-type containing 19 protein. This protein plays a crucial role in intracellular signaling pathways and membrane trafficking processes. The inhibitors within this class are specifically designed to bind to the ZFYVE19 protein and disrupt its normal function, which is essential for the proper distribution of membrane components and the regulation of receptor signaling. By hindering the activity of ZFYVE19, these compounds can effectively alter the dynamics of membrane tubulation, protein sorting, and endocytic trafficking. The specificity of these inhibitors is critical, as they must selectively interact with the ZFYVE19 protein without affecting the myriad of other zinc finger proteins that operate within the cell. The chemical structures of these inhibitors are typically complex, often containing multiple rings that allow for tight binding to the unique structure of the ZFYVE19 protein domain.
The mode of action for ZFYVE19 inhibitors is rooted in their ability to prevent the association of the ZFYVE19 protein with phosphatidylinositol 3-phosphate (PI3P) found in the membrane of endosomes. This interaction is pivotal for the recruitment of ZFYVE19 to the endosomal membranes, a step that is integral to its role in mediating endosome function. By blocking this association, ZFYVE19 inhibitors effectively impair the protein's ability to execute its role in the endosomal sorting process, which can lead to a cascade of effects on cellular homeostasis and signaling. The inhibition of ZFYVE19 disrupts the balance of endocytic trafficking, potentially altering the signaling pathways that are dependent on the proper localization of receptors and other membrane proteins. This mechanism of action is highly targeted, reflecting the inhibitors' design to specifically interfere with the ZFYVE19 protein's interaction with PI3P, rather than a broad, non-specific disruption of cellular functions.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). ZFYVE19, as a FYVE domain-containing protein, may interact with PI3K products such as PIP3. Inhibition of PI3K by wortmannin could reduce the availability of PIP3, which is necessary for ZFYVE19 membrane recruitment and function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another chemical that inhibits PI3K activity. Similar to wortmannin, LY294002’s inhibition of PI3K leads to decreased PIP3 levels, potentially impairing ZFYVE19’s interaction with PIP3-enriched membranes, thus inhibiting its function. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $65.00 $261.00 | 113 | |
3-Methyladenine is an autophagy inhibitor that acts by inhibiting PI3K. Given that ZFYVE19 is implicated in membrane trafficking and autophagy, inhibition of PI3K could disrupt these processes and subsequently ZFYVE19 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which in turn inhibits the MAPK/ERK pathway. ZFYVE19 may be involved in signaling pathways that are regulated by the MAPK/ERK pathway. Inhibition by PD98059 could indirectly decrease ZFYVE19’s activity by altering downstream signaling events. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is an inhibitor of p38 MAPK. As ZFYVE19 might be involved in pathways modulated by stress responses that are p38 MAPK-dependent, inhibiting p38 MAPK with SB203580 could reduce the functional activity of ZFYVE19. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor and can inhibit the mTOR pathway which is involved in autophagy, a process that ZFYVE19 has been linked to. Inhibition of mTOR by Rapamycin could, therefore, decrease the functional activity of ZFYVE19 involved in autophagic processes. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1 is a potent autophagy inhibitor that specifically targets ubiquitin-specific peptidase 10 (USP10) and USP13. As ZFYVE19 is associated with autophagy, Spautin-1 could indirectly decrease ZFYVE19 activity through inhibition of autophagosome maturation. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a V-ATPase inhibitor that prevents autophagosome and lysosome fusion. As ZFYVE19 is implicated in autophagic trafficking, inhibiting this fusion with Bafilomycin A1 could decrease ZFYVE19’s role in autophagy. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore is a GTPase inhibitor that targets dynamin, which is crucial for vesicular trafficking and release. By inhibiting dynamin, Dynasore could impair vesicular processes that ZFYVE19 is associated with, leading to decreased functional activity of ZFYVE19. | ||||||
ML 141 | 71203-35-5 | sc-362768 sc-362768A | 5 mg 25 mg | $137.00 $512.00 | 7 | |
ML141 is a selective inhibitor of Cdc42, a member of the Rho family of GTPases. Since ZFYVE19 is involved in actin cytoskeleton organization, inhibiting Cdc42 could affect cellular dynamics and processes in which ZFYVE19 participates, thus indirectly inhibiting its function. | ||||||